NCT06902376 - XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

August 31, 2028

Conditions

Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors

Interventions

BIOLOGICAL

Cemiplimab

Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.

DRUG

XL092

XL092 will be administered at a dose of 100mg PO daily for 8 weeks (weeks 1-8)

Trial Locations (2)

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

02215

NOT_YET_RECRUITING

Dana Farber/Harvard Cancer Center, Boston